Lasmar MF, et al. - A sample of 469 patients were allotted into four groups (G) based on immunological risk of rejection, ie, G1, low risk, not sensitized recipients, solid-phase immunoassay with single antigen beads (SPI-SAB) < 10%; G2, medium risk I, sensitized recipients, SPI-SAB ≥ 10 < 50%; G3, medium risk II sensitized; and G4, high risk, sensitized recipients, SPI-SAB- donor-specific antibody positive by the researchers in order to assess the impacts of immunotherapy by immunobiologic thymoglobulin on graft survival during a 9-year period in kidney-transplanted patients with different immunological profiles. A total of 42 of 255 patients who received a kidney from a living donor (LD) from all groups (G) had T-cell–mediated rejection (TCMR) and four (G1) lost their grafts, 8 had antibody-mediated rejection (AMR), and two lost their graft in G1 and G4. Thirty-seven of 214 patients who received a kidney from deceased donors (DD) had TCMR with one lost graft in G1. AMR was demonstrated in 13 patients, with three losses noted in G2. Statistical variations between the groups in the 9-year graft survival rate were seen only in the comparison of G1 vs G2 and G2 vs G4 for DD. No statistical variations were noted for LD. Immunotherapy induction was related to betterment of outcomes, graft function, and survival in patients treated with immunotherapy vs patients who did not receive induction therapy. Moreover, immunotherapy should be utilized for all individuals transplanted with kidneys from deceased donors.